GVK Biosciences and Quantitative Solutions (QS) entered a strategic partnership to develop and market clinical trial outcome databases. The databases will be designed to capture summary-level data for the clinical safety and efficacy outcomes from publicly available data sources.


GVK BIO will distribute globally existing QS databases in five indications immediately: rheumatoid arthritis and psoriasis, chronic HCV, neuropathic pain, osteoporosis (postmenopausal), and major depression. GVK BIO and QS plan to jointly develop and market additional databases in dyslipidemia, schizophrenia, alzheimer’s, and other indications in the near future.


The aim is for the clinical trial outcome databases to assist drug development teams to conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies. The databases will be supported by customization and M&S consulting services provided by GVK BIO and QS, respectively.








This site uses Akismet to reduce spam. Learn how your comment data is processed.